Takeda announced that the FDA has approved Nesina (alogliptin), Oseni (alogliptin and Pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts...
Please login or register first to view this content.
Login Register